TOP TEN perturbations for P98179 (Homo sapiens)

Organism: Homo sapiens
Gene: P98179
Selected probe(set): 208319_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P98179 (208319_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

HIV-associated neurocognitive disorder study 3 (HIVE) / HIV-associated neurocognitive disorder study 2 (HIVE)

Relative Expression (log2-ratio):-4.2518377
Number of Samples:2 / 2
Experimental HIV-associated neurocognitive disorder study 3 (HIVE)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with HIV encephalitis (HIVE). HIVE was limited to the basal ganglia. The patients did not receive any antiretroviral therapy (ART).
Control HIV-associated neurocognitive disorder study 2 (HIVE)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with HIV encephalitis (HIVE). The patients received an antiretroviral therapy (ART).

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-4.0090675
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

wound healing study 2 (ex vivo; AG1478) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-2.9557724
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; AG1478)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing AG1478 for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 10 micromolar AG1478 (dissolved in DMSO). The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. AG1478 is EGFR kinase inhibitor. ATC code:---
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

Parkinson's disease study 10 / normal postmortem substantia nigra tissue

Relative Expression (log2-ratio):-2.7523623
Number of Samples:16 / 9
Experimental Parkinson's disease study 10
Substantia nigra tissue from postmortem brain of Parkinson's disease (PD) patients.
Control normal postmortem substantia nigra tissue
Substantia nigra tissue from postmortem brain of normal controls.

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):-2.7485123
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-2.7077293
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-2.6935215
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; DMSO)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin.
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):2.619441
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

B-CLL study 9 (CD19+; CD5+; Wnt3a) / B-CLL study 9 (CD19+; CD5+)

Relative Expression (log2-ratio):-2.523611
Number of Samples:6 / 172
Experimental B-CLL study 9 (CD19+; CD5+; Wnt3a)
CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL) and treated with Wnt3a for 48 hours. It is not clear whether the concentration of Wnt3a was 5ng/ml or 50ng/ml. B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.
Control B-CLL study 9 (CD19+; CD5+)
CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL). B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.

immunoglobulin (IVIG) study 2 (responder) / Kawasaki disease study 2 (responder)

Relative Expression (log2-ratio):2.5222197
Number of Samples:4 / 4
Experimental immunoglobulin (IVIG) study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained 36-48 hours after treatment with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness. ATC code:---
Control Kawasaki disease study 2 (responder)
Whole blood samples from subjects with Kawasaki disease obtained prior to therapy with intravenous immunoglobulins (IVIG; 2g/kg for 1 day). Based on Egami score, patients were predicted to have good response to the therapy. The Egami scoring system identifies age, days of illness, platelet count, C-reactive protein and alanin aminotransferase to predict resistance to the IVIG treatment and is highly sensitive and specific in Japanese patients. All patients received aspirin (30mg/kg/day) during acute stage of illness.